Fatherhood and addictive disorders: experiences and support needs – results of a qualitative interview study

ObjectivesParental addictive disorders are a major public health problem. Despite already known negative effects, the parental role of men seeking help is rarely acknowledged within addiction support services. This study aims to identify existing relations between fatherhood and addiction, and the resulting support needs of affected fathers.MethodsFor data collection 15 fathers with addictive disorders were interviewed by using qualitative, guided interviews. The data material was analyzed using qualitative content analysis.ResultsThe effects of addictive disorders on fatherhood are predominantly unfavorable. Conversely, fatherhood can have consumption-reducing as well as consumption-increasing effects. In this context, five topics were identified in which fathers expressed specific support needs. Particularly fathers with substance use disorders expressed their need for further support, while fathers with behavioral addictions expressed a lesser need.ConclusionsPaying attention to fatherhood in the context of addiction services provides a starting point for increasing the motivation to change. Individual support needs should be considered when implementing father-specific programs. Not only the fathers themselves, but also their children can benefit from successful treatment and expected changes in fatherhood.

Targeted stool metabolomics suggests exploratory catecholamine- and tryptophan-linked metabolic features in autism spectrum disorder

BackgroundGut-brain axis dysregulation and microbiome-linked metabolic alterations have been implicated in autism spectrum disorder (ASD), but the contribution of gut-derived neuroactive metabolites remains incompletely characterized.MethodsWe conducted a cross-sectional case-control study of 59 participants (32 ASD, 27 controls) and quantified 18 stool metabolites related to catecholamine synthesis, inhibitory neurotransmission, and tryptophan-linked NAD+-precursor metabolism using targeted liquid chromatography-tandem mass spectrometry. Group differences were assessed using fold-change analysis and linear models adjusted for age and sex. Random forest models evaluated classification performance, and within-group Spearman correlations were used to examine metabolic relationships.ResultsNorepinephrine showed the largest increase in ASD, whereas dopamine and tetrahydrobiopterin exhibited nominal group differences that did not remain significant after correction for multiple testing. A three-metabolite panel comprising tetrahydrobiopterin, γ-aminobutyric acid, and kynurenine showed exploratory discrimination between groups (area under the receiver operating characteristic curve = 0.750, 95% confidence interval 0.622–0.878), but this performance requires external validation. Correlation analysis revealed conserved bile acid coupling in both groups. In controls, tryptophan was positively associated with kynurenine, whereas this relationship was not observed in ASD. Instead, ASD samples showed broader associations between tryptophan and metabolites linked to neurotransmission and NAD+-precursor metabolism.ConclusionStool metabolite profiling revealed altered organization of tryptophan- and catecholamine-linked metabolic associations in ASD and identified a small metabolite panel with exploratory discriminative potential. These findings provide a foundation for future studies examining gut-derived neuroactive metabolites in ASD and their relationship to gut-brain axis biology.

Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets

BackgroundCompound liquorice tablets is a cough-suppressing compound formulation containing opium powder and liquorice. With the strict regulation of traditional opioids, this medication has emerged as a novel alternative for substance abuse due to its easy accessibility and low cost; however, its addiction potential and severe adverse complications remain underrecognized and insufficiently addressed in clinical practice.Case summaryThe patient is a 29-year-old male who began self-medicating with compound liquorice tablets for a dry cough after COVID-19 infection. His daily dosage gradually escalated to 200–600 tablets within two years, resulting in established drug dependence. Two days after discontinuing the medication, he developed delirium manifested as confusion, disorientation, visual hallucinations and psychomotor agitation, accompanied by palpitations, hypertension, tremors, rhinorrhea, vomiting, severe hypokalemia, and bilateral lower limb edema. Organic brain diseases were excluded by systematic examinations. According to the ICD-10 diagnostic criteria, he was diagnosed with opioid-induced mental and behavioral disorders, hypokalemia and hypertension. We implemented a benzodiazepine tapering regimen to control delirium and sympathetic excitation associated with withdrawal symptoms, combined with antidepressants and antipsychotics to improve mood, anxiety, and psychotic symptoms, Under the guidance of a cardiologist, we actively managing hypertension and correcting internal environmental disturbances. Following comprehensive management, the patient’s withdrawal symptoms and delirium resolved, with stable emotional state and blood pressure, resulting in successful withdrawal.ConclusionThis is the first reported case of delirium caused by withdrawal from compound liquorice tablets. It provides preliminary insights for clinical identification, diagnosis, and multidisciplinary management of dependence on compound liquorice tablets, as well as related withdrawal symptoms and complications. This case also alerts to the emerging risk of abuse associated with new substances such as compound liquorice tablets and underscores the need for stricter prescription controls and patient education regarding the risks of abuse.

Mental health stigma among nursing students: current status and intervention strategies— an integrative review

ObjectiveAims to synthesize the current evidence on the prevalence of mental health stigma among nursing students and to summarize the interventions that have been developed and evaluated to reduce such stigma.MethodsA comprehensive search was conducted across PubMed, CINAHL, and Web of Science databases for peer-reviewed studies published in English between January 2018 and June 2024.ResultsA total of 25 studies were included. The prevalence of mental health stigma among nursing students was found to be moderate to high. Stigma manifested in various forms, including negative attitudes toward patients, internalized shame, and public stigma directed at nursing students themselves. Interventions such as mental health training, empathy enhancement programs, and clinical internships demonstrated varying degrees of effectiveness in reducing stigma, with multi-component interventions showing the most promise.ConclusionMental health stigma among nursing students is a persistent and multifaceted issue that requires targeted strategies to address. Enhancing mental health education, increasing clinical exposure, and implementing comprehensive intervention programs are essential steps to reduce stigma and support the development of compassionate, skilled nursing professionals.

Biomarkers Could Help in Antidepressant Choice

Antidepression treatment based on a person’s individual biomarkers could help determine which of the world’s most popular medications to use, a clinical trial suggests.

The SMART Trial to Predict Anhedonia Response to Antidepressant Treatment results suggest that behavioral, brain, and clinical data could together determine the optimal antidepressant to choose before a person starts treatment.

There were no significant primary endpoint differences in depression outcomes between participants who received bupropion or sertraline based on biomarkers identified in the prior Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study.

But people negative for biomarkers with both drugs had significantly worse depression symptom trajectories than those who had at least one positive biomarker, regardless of the drug they received.

Response rates among participants with both biomarkers were almost double that of those without any biomarkers, with those who had at least one biomarker having an intermediate response.

“Our results suggest that we could boost response rate by using two sets of biomarkers previously identified in the EMBARC study, making an important contribution to advancing the goals of precision psychiatry,” reported Peter Zhukovsky, PhD, from Harvard Medical School, and co-workers in Nature Mental Health.

“Ultimately, we strongly hope these advances will enable personalized treatment guidance to accelerate and boost antidepressant benefits.”

Treatment for depression is often still trial and error, with symptoms improving in only half the people taking an antidepressant. This could be due to treatments not being chosen based on people’s individual characteristics.

Finding markers that predict response to different antidepressants could therefore provide patients and clinicians with valuable information to guide treatment choice.

The trial was among the first to investigate how treatment could be guided using clinical information such as responses to questionnaires, behavioral information such as performance in computerized tasks, and brain data such as magnetic resonance imaging (MRI) scans.

It was carried out as part of the Wellcome Leap Multi-Channel Psych Program effort to double the number of people who respond to the first treatment they try for depression via the integration of multimodal biomarkers.

Firstly, the researchers investigated biomarker models that predicted response to the selective serotonin reuptake inhibitor (SSRI) sertraline or the norepinephrine-dopamine reuptake inhibitor bupropion using the EMBARC study.

The treatment-assignment algorithm that was developed generated two marker-based indications for each patient—one for bupropion and sertraline—with the predictive model achieving a cross-validated area under the curve of 0.86 and 0.66, respectively.

The team then examined whether antidepressant response could be boosted using their created biomarker combination of a functional MRI imaging marker, reward learning and sensitivity, cognitive control, the clinical variables of depression severity and neuroticism, and the demographic variable of employment status.

After analyzing these biomarkers among participants, who had major depressive disorder, the group was randomly assigned to receive a full 8-week course of an SSRI or non-SSRI.

The primary outcome was the change in depression severity from pretreatment baseline to eight weeks after the start of treatment, with no significant differences in treatment outcomes for those assigned a drug consistent versus inconsistent with their biomarkers.

This, the researchers say was possibly due to the limited power to detect moderate effects.

However, significant differences emerged in symptom reduction trajectories for those with positive markers for both medications, with a response rate of 71.4% compared with 65.4% for those with a positive biomarker for either drug and 42.9% for those with two negative markers.

The authors concluded: “We found that, relative to patients with two negative markers, those with one or two markers were characterized by significantly larger reduction in depressive symptoms, showing that biomarker-guided treatment selection can boost efficacy for two of the most widely prescribed antidepressants around the world.”

The post Biomarkers Could Help in Antidepressant Choice appeared first on Inside Precision Medicine.

South Korea’s hottest new bachelors are chip workers

Baek, a 35-year-old manager at the South Korean semiconductor titan SK Hynix, was enrolled in Sunoo, a matchmaking company based in Seoul, a year ago. In a move typical of anxious South Korean parents, his mother signed him up, hoping to find a good wife for her son.

Lately, says Baek (who asked to be referred to by his last name to protect his privacy), he and his coworkers are having better luck finding dates than they used to, perhaps because of the dazzling bonuses they just got. Flush with eye-popping profits from the AI chip boom, SK Hynix struck a landmark deal last year with its labor union to pay out 10% of operating profits to employees, which translates to an extra $476,000 per employee this year. A similar agreement and sizable lump sum followed for Samsung workers this May.

With their newfound wealth, chip workers like Baek have become the most sought-after bachelors and bachelorettes in South Korea. “I have a coworker who’s perpetually going on blind dates, and he’s been getting so many recently,” says Baek. “For the past few months, I’ve been getting many blind dates too, perhaps because of the bonuses I got.”

Lately, young South Koreans joke online that the best outfit to wear on a blind date is an SK Hynix uniform. 

The AI chip boom is changing the social fabric of South Korea by minting a new elite of “silicon-collar” workers earning about 20 times as much as the average South Korean. Although it’s helping some chip workers to find relationships, it’s also fueling fears of a deepening wealth disparity—and a loud public debate about inequality.

Love in the time of chips

South Korea is the epicenter of the chip boom fueling the AI race. Samsung and SK Hynix supply the vast majority of the world’s high-bandwidth memory (HBM) chips, which power Nvidia’s AI accelerators—the GPUs used to train AI models. As AI companies spend hundreds of billions of dollars on building data centers around the world, demand for HBMs is rising beyond what suppliers can keep up with, driving their prices to unprecedented levels. Samsung and SK Hynix are raking in record profits as a result. 

South Korea’s economy now orbits the two chip giants. In May, both companies topped $1 trillion in market value. And chip exports helped fuel a 1.7% surge in South Korea’s gross domestic product in the first quarter of 2026. South Korea’s main equity index, Kospi, has nearly tripled over the past year, becoming the best-performing market in the world.

Swimming in cash, chip workers are going on shopping sprees in department stores near the “semicon belt” fabs—splurging on everything from lavish furniture and electronic appliances to jewelry and watches. They’re also snapping up homes near the commuter-shuttle routes that ferry workers to campus. And they’re shelling out for matchmakers.

“Quite a lot of people ask me if I can introduce them to chip workers,” says Lee Sung-mi, a matchmaker at Sunoo, who has been playing Cupid for chip workers for years. “In fact, people who once rejected them are asking to be matched with them again, now that their salaries and bonuses have shot so far above what everyone else earns.”

One woman who lives in Gangnam, a ritzy district in Seoul lined with luxury high-rises and designer boutiques, previously turned down a chip worker at SK Hynix because his fab was too far out in Icheon, a rural city about 50 miles southeast of Seoul that’s dotted with rice farms and manufacturing plants. But in May, she asked her matchmaker to set them up again. They’ve now been dating for a month.                                                                                                                                                                                                                                                                                                                                                                                                                             

In South Korea, matchmaking companies evaluate their clients on a long list of criteria such as education, job, income, looks, and family background, including whether their aging parents have saved enough for retirement. In an economy where housing prices and child care costs are soaring, competition for jobs is fierce, and the social safety net is thin, a good job is the ultimate dating credential—all the more coveted at a time when many young South Koreans are forgoing marriage and children altogether, seeing family life as an unaffordable dream.

Every client at Sunoo gets a spouse rating, determined by an algorithm that assigns scores for each criterion. Since their hefty bonuses were announced, the job ratings of Samsung employees have risen from 80 to 84, while those of SK Hynix employees climbed from 78 to 82. Scores above 90 are reserved for doctors and lawyers. Long prized as paragons of prestige and wealth, they’re now close to being overtaken by chip workers. A score of 99, the highest possible rating, is earmarked for heads of state.  

Their new status is reshaping how chip workers themselves approach dating. “Chip workers from Samsung and SK Hynix are enrolling in our services because they feel more financially ready,” says Lee. “They’re also becoming pickier, as they feel like they’re now in a good position. The women want to meet men with higher incomes and better jobs, and the men want to meet younger and better-looking women with better jobs.” 

An SK Hynix engineer in her 40s, who was once desperate to get married as soon as possible, started turning down men she would’ve dated before the chip boom. Lately, showered with more matches, she’s been sifting through her suitors more carefully. “She now has peace of mind and wants to take her time to meet someone better,” says Lee.

A mixed blessing

While chip workers enjoy the fruits of their labor, the bonus bonanza is stoking anxieties among other South Koreans. “When wealth disparity is no longer a mere difference of income but, rather, a difference in identity … it can fuel social conflict,” says Se-eun Jung, an economist at Inha University. 

Earlier this month, the Bank of Korea warned that the chip boom will create a “K-shaped” economy, where a handful of workers race ahead while everyone else falls behind. The windfall, the bank said, is flowing to high income earners and then barely trickling out to the broader economy. Such polarization could erode people’s motivation to work by narrowing the path to upward mobility, it cautioned. 

Workers in other industries are venting online about feeling demoralized by the ballooning wealth gap. “The one-billion-won ($650,000) bonuses have crushed my motivation to work. I have no energy when I teach,” an employee of the Seoul Metropolitan Office of Education wrote on Blind, an app where employees can discuss their workplaces anonymously. Others are giving up the job hunt, lamenting that years of working at a small company could never match a year’s bonus at Samsung. 

In a Facebook post in May, presidential policy chief Kim Yong-beom proposed paying an “AI dividend” to citizens by taxing AI profits. The idea sparked a heated public debate over whether the government should redistribute gains from the chip boom. Some argue that the industry is indebted to the society that has educated its engineers, subsidized its infrastructure, and provided tax credits. Others counter that the profits are already being shared with the public as stocks.

Then there’s the question of how long this new social class will last. The semiconductor industry is notoriously cyclical; AI spending may cool, or rival chipmakers could catch up. There’s also the risk that chip workers will be replaced by automation. Samsung announced in March that it plans to fully automate its fabs by 2030, drawing backlash from chip workers. 

Although he doesn’t know how long the boom will last, chip workers like Baek are riding high. “These days, we say we want to work hard and bury our bones here [at SK Hynix],” he says. “And I hope I can find [a wife] similar to me.”

MH-POWER for College Students on the Spectrum

Conditions: College Students on the Autism Spectrum With Mental Health Challenges

Interventions: Behavioral: The MH-POWER program

Sponsors: University of Texas Rio Grande Valley; The American Occupational Therapy Foundation

Recruiting